{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T03:16:38Z","timestamp":1771038998665,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2023,11,5]],"date-time":"2023-11-05T00:00:00Z","timestamp":1699142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Haemophilia"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Introduction<\/jats:title><jats:p>Several well\u2010established clinical laboratory methods are available to measure von Willebrand factor (VWF) in plasma samples, but few data are available on their use for analysing recombinant VWF (rVWF).<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim<\/jats:title><jats:p>To evaluate how clinical diagnostic laboratories analyse rVWF and plasma\u2010derived VWF (pdVWF) spiked in vitro into VWF\u2010deficient plasma using quantitative protein and functional assays of VWF.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Human VWF\u2010deficient plasma samples were spiked with rVWF (vonicog alfa; Takeda) or pdVWF\/factor VIII (pdVWF\/FVIII; antihemophilic factor\/VWF complex [human], CSL Behring), each at final concentrations of 1.0, 0.6, 0.2, 0.1 IU\/mL VWF:ristocetin cofactor activity (VWF:RCo) according to labelled VWF activity. The ISTH SSC secondary coagulation standard was used as a control. Participating laboratories received three sets of these blinded aliquots. Mean results per assay were compared with the expected potency based on the labelled VWF:RCo activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Among 39 laboratories, the most commonly established assay was VWF:RCo; 22 laboratories reported data from 2214 tests. Despite a trend to lower values, VWF:RCo activities for rVWF were in agreement with target concentrations (71%\u2013109%), whereas VWF:platelet glycoprotein Ib (VWF:GpIb) and VWF collagen\u2010binding activity (VWF:CB) assays gave high recoveries (up to 132% and 127%, respectively). In contrast, pdVWF\/FVIII was substantially underestimated by VWF:GpIb and VWF:CB assays (56%\u201386% recoveries), whereas the VWF:RCo assay gave recoveries of 47%\u2013112% for pdVWF\/FVIII.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The results of VWF assays used in clinical laboratories differ between rVWF and pdVWF, particularly for VWF:GpIb and VWF:CB assays. These differences may arise from the higher multimeric structure of rVWF compared to pdVWF.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hae.14892","type":"journal-article","created":{"date-parts":[[2023,11,6]],"date-time":"2023-11-06T03:34:41Z","timestamp":1699241681000},"page":"151-160","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["In vitro field study and worldwide survey assessing how clinical haemostasis laboratories analyse recombinant and plasma\u2010derived von Willebrand factor products"],"prefix":"10.1111","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6161-1556","authenticated-orcid":false,"given":"Peter L.","family":"Turecek","sequence":"first","affiliation":[{"name":"Baxalta Innovations GmbH a Takeda company  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Ilk","sequence":"additional","affiliation":[{"name":"Takeda Manufacturing Austria AG  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Herbert","family":"Gritsch","sequence":"additional","affiliation":[{"name":"Baxalta Innovations GmbH a Takeda company  Vienna Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2023,11,5]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003265"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1601561"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040403"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.04.001"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12763"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12964"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-08-528398"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0040-1713735"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.102143"},{"key":"e_1_2_11_11_1","unstructured":"WHO International Standard.WHO 3rd International Standard von Willebrand Factor Concentrate NIBSC code: 18\/248. Instructions for use (Version 1.0 Dated 13\/06\/2022).2022. Accessed March 7 2023.https:\/\/www.nibsc.org\/documents\/ifu\/18\u2010248.pdf"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-971815"},{"key":"e_1_2_11_13_1","unstructured":"European Pharmacopoeia 11.0. Assay of human von Willebrand factor. Chapter 2.7.21. Page 305. Accessed April 1 2023.https:\/\/pheur.edqm.eu\/home"},{"key":"e_1_2_11_14_1","unstructured":"WHO International Standard. 6th International Standard Factor VIII \/von Willebrand factor plasma and International reference reagent for VWF:GPIbM and VWF:GPIbR methods. NIBSC code: 07\/316. Instructions for use (Version 3.01 Dated 02\/04\/2019).2019.https:\/\/www.nibsc.org\/documents\/ifu\/07\u2010316.pdf"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.14465"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2018.07.007"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.2147\/JBM.S377126"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.5482\/HAMO-17-04-0018"},{"key":"e_1_2_11_19_1","doi-asserted-by":"crossref","unstructured":"HubbardAR HamillML MalineeB SallyAB HeathAB Value assignment of the proposed 2nd international standard for von Willebrand Factor concentrate human (09\/182). WHO\/BS\/10.2147. World Health Organization.2010.https:\/\/apps.who.int\/iris\/handle\/10665\/70520","DOI":"10.1111\/j.1538-7836.2011.04365.x"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/hae.12064"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jth.14319"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijlh.12218"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-0716-3175-1"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1753528"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pathol.2021.07.001"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1055\/s-0042-1754331"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hae.14892","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T13:08:48Z","timestamp":1712322528000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hae.14892"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,5]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1111\/hae.14892"],"URL":"https:\/\/doi.org\/10.1111\/hae.14892","archive":["Portico"],"relation":{},"ISSN":["1351-8216","1365-2516"],"issn-type":[{"value":"1351-8216","type":"print"},{"value":"1365-2516","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,5]]},"assertion":[{"value":"2023-05-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-11-05","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}